Pharmaxis reports positive interim data from myelofibrosis study

CEO Gary Phillips said, “We are confident that these results, if repeated in the whole study population, will satisfy regulatory requirements to continue the development of PXS-5505 in myelofibrosis and also excite clinicians, patients and industry groups who are closely following our progress with this novel mechanism." …